Top Markets
Coin of the day
AIM ImmunoTech Inc. AIM ImmunoTech Inc.

AIM ImmunoTech Inc.

AIM
Rang in Aktien #38731
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida,... AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
Aktienkurs
$0.2446
Marktkapitalisierung
$832.51K
Veränderung (1 Tag)
-5.30%
Veränderung (1 Jahr)
-89.89%
Land
US
Handel AIM ImmunoTech Inc. (AIM)

Kategorie

Dividendenrendite-Verlauf für AIM ImmunoTech Inc. (AIM)
Dividendenrendite (TTM) von AIM ImmunoTech Inc. (Aktienkürzel: AIM) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für AIM ImmunoTech Inc. (AIM) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber